Compare GSM & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSM | ARVN |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 964.9M | 781.0M |
| IPO Year | 2015 | 2018 |
| Metric | GSM | ARVN |
|---|---|---|
| Price | $3.81 | $11.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | $6.00 | ★ $15.35 |
| AVG Volume (30 Days) | ★ 1.1M | 770.9K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $23.36 | N/A |
| Revenue Next Year | $17.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.97 | $5.90 |
| 52 Week High | $5.74 | $14.22 |
| Indicator | GSM | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 29.63 | 33.59 |
| Support Level | $3.59 | $9.02 |
| Resistance Level | $4.56 | $14.03 |
| Average True Range (ATR) | 0.25 | 0.67 |
| MACD | -0.11 | -0.29 |
| Stochastic Oscillator | 4.89 | 9.10 |
Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's business segments include North America- Silicon, North America -Silicon Alloys; Europe Manganese; Europe Silicon Metals; Europe -Silicon Alloys, South Africa Silicon Metals, South Africa-Silicon Alloys, and Other segments The primary raw materials company uses to produce its electrometallurgy products includes its coal and quartz mining operations and its silicon metal and ferroalloy production.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.